Global Medical REIT Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Subsequent Events

Subsequent Events

9 Months Ended

Sep. 30, 2025

Note 10 – Subsequent Events

On October 8, 2025, the Company entered into the Amended and Restated Credit Facility, which contains the following material amendments to the Company’s Credit Facility:

●

Extends the initial maturity date of the existing $400 million Revolver component of the Credit Facility to October 2029 with two, six-month extension options available at the Company’s election to extend the maturity to October 2030; and

●

Extends the maturity of the existing $350 million Term Loan A, dividing it into three term loans structured as follows:

●$100 million term loan maturing in October 2029 (“Term Loan A-1”);

●$100 million term loan maturing in October 2030 (“Term Loan A-2”); and

●$150 million term loan maturing in April 2031 (“Term Loan A-3”); and

●

Removes the previous 0.10% (10 basis point) SOFR credit spread adjustment on all Amended and Restated Credit Facility borrowings.

The Credit Facility’s pricing grid, $150 million Term Loan B that matures in February 2028, and $500 million accordion remain unchanged.

In connection with the Amended and Restated Credit Facility, on October 7, 2025, the Company entered into $350 million of new forward starting interest rate swaps to fully hedge the SOFR component of the three Term Loan A tranches through their respective maturities.

The existing $350 million Term Loan A fixed rate SOFR swaps remain in place, resulting in an all-in fixed interest rate of 2.85% on this debt through the swap maturities in April 2026.

At closing of the Amended and Restated Credit Facility, the weighted average term of the Company’s debt, including the drawn Revolver component, was 4.4 years.